本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Artiva Biotherapeutics, Inc.

5.16
-0.3000-5.49%
盤後5.260.1000+1.94%16:21 EDT
成交量:10.65萬
成交額:56.82萬
市值:1.28億
市盈率:-1.50
高:5.67
開:5.55
低:5.16
收:5.46
52周最高:7.75
52周最低:1.47
股本:2,471.67萬
流通股本:538.17萬
量比:1.20
換手率:1.98%
股息:- -
股息率:- -
每股收益(TTM):-3.4309
每股收益(LYR):-3.4309
淨資產收益率:-56.55%
總資產收益率:-32.97%
市淨率:1.16
市盈率(LYR):-1.50

資料載入中...

公司資料

公司名字:
Artiva Biotherapeutics, Inc.
交易所:
NASDAQ
成立時間:
2019
員工人數:
104
公司地址:
5505 Morehouse Drive,Suite 100,San Diego,California,United States
郵編:
92121
電話:
傳真:
- -
簡介:
Artiva Biotherapeutics, Inc.於2019年2月14日在特拉華州註冊成立。該公司是一家臨床階段的生物技術公司,專註於為患有破壞性自身免疫性疾病和癌症的患者開發基於自然殺傷(NK)細胞的療法。

董事

名稱
職位
Fred Aslan
President,Chief Executive Officer and Director
Brian Daniels
Chairperson
Alison Moore
Director
Daniel Baker
Director
Diego Miralles
Director
Elaine Sorg
Director
Elizabeth Hougen
Director
Laura Stoppel
Director

股東

名稱
職位
Fred Aslan
President,Chief Executive Officer and Director
Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Heather Raymon
Senior Vice President of Research and Early Development
Neha Krishnamohan
Chief Financial Officer and Executive Vice President of Corporate Development
Thad Huston
Chief Financial Officer,Principal Accounting Officer and Principal Financial Officer
Christopher P. Horan
Chief Technical Operations Officer
Subhashis Banerjee
Chief Medical Officer